Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Increase in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 123,800 shares, an increase of 56.5% from the August 15th total of 79,100 shares. Currently, 24.5% of the company’s shares are short sold. Based on an average daily trading volume, of 240,200 shares, the short-interest ratio is currently 0.5 days. Based on an average daily trading volume, of 240,200 shares, the short-interest ratio is currently 0.5 days. Currently, 24.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Salarius Pharmaceuticals to a “sell” rating in a research report on Friday, August 22nd.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ SLRX remained flat at $5.29 during trading hours on Monday. The company had a trading volume of 2,843,280 shares, compared to its average volume of 161,855. The business’s fifty day simple moving average is $8.08 and its 200-day simple moving average is $11.02. The stock has a market capitalization of $2.70 million, a price-to-earnings ratio of -0.12 and a beta of 0.51. Salarius Pharmaceuticals has a 1 year low of $4.50 and a 1 year high of $108.00.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($33.00) by $32.55.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.